These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 31057401)

  • 1. Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation.
    Behnammanesh G; Durante ZE; Peyton KJ; Martinez-Lemus LA; Brown SM; Bender SB; Durante W
    Front Pharmacol; 2019; 10():362. PubMed ID: 31057401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1.
    Behnammanesh G; Durante GL; Khanna YP; Peyton KJ; Durante W
    Redox Biol; 2020 May; 32():101527. PubMed ID: 32278282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinctive effects of SGLT2 inhibitors on angiogenesis in zebrafish embryos.
    Huttunen R; Sainio A; Hjelt A; Haapanen-Saaristo AM; Määttä J; Rummukainen P; Paatero I; Järveläinen H
    Biomed Pharmacother; 2022 Dec; 156():113882. PubMed ID: 36265308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canagliflozin Inhibits Human Endothelial Cell Inflammation through the Induction of Heme Oxygenase-1.
    Peyton KJ; Behnammanesh G; Durante GL; Durante W
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms.
    Mancini SJ; Boyd D; Katwan OJ; Strembitska A; Almabrouk TA; Kennedy S; Palmer TM; Salt IP
    Sci Rep; 2018 Mar; 8(1):5276. PubMed ID: 29588466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
    Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
    Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.
    Kaji K; Nishimura N; Seki K; Sato S; Saikawa S; Nakanishi K; Furukawa M; Kawaratani H; Kitade M; Moriya K; Namisaki T; Yoshiji H
    Int J Cancer; 2018 Apr; 142(8):1712-1722. PubMed ID: 29205334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
    Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
    Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of SGLT2 Inhibitors Beyond Glycemic Control - A Focus on Metabolic, Cardiovascular and Renal Outcomes.
    Minze MG; Will KJ; Terrell BT; Black RL; Irons BK
    Curr Diabetes Rev; 2018; 14(6):509-517. PubMed ID: 28814245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
    Chu C; Lu YP; Yin L; Hocher B
    Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can we go beyond surrogates?
    Drexler A
    J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK.
    Evans M; Achha S; Neslusan C
    Diabetes Ther; 2017 Oct; 8(5):1175-1185. PubMed ID: 28948541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
    Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
    BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT2 Inhibitors May Restore Endothelial Barrier Interrupted by 25-Hydroxycholesterol.
    Pawlos A; Broncel M; Woźniak E; Markiewicz Ł; Piastowska-Ciesielska A; Gorzelak-Pabiś P
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms.
    Semo D; Obergassel J; Dorenkamp M; Hemling P; Strutz J; Hiden U; Müller N; Müller UA; Zulfikar SA; Godfrey R; Waltenberger J
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36835891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy.
    Herat LY; Matthews JR; Rakoczy EP; Schlaich MP; Matthews VB
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):83. PubMed ID: 37114550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
    Vivian EM
    Drugs Context; 2014; 3():212264. PubMed ID: 25598831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polypharmacology of clinical sodium glucose co-transport protein 2 inhibitors and relationship to suspected adverse drug reactions.
    Matharu K; Chana K; Ferro CJ; Jones AM
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00867. PubMed ID: 34586753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration.
    Villani LA; Smith BK; Marcinko K; Ford RJ; Broadfield LA; Green AE; Houde VP; Muti P; Tsakiridis T; Steinberg GR
    Mol Metab; 2016 Oct; 5(10):1048-1056. PubMed ID: 27689018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 inhibitor empagliflozin promotes revascularization in diabetic mouse hindlimb ischemia by inhibiting ferroptosis.
    Han JX; Luo LL; Wang YC; Miyagishi M; Kasim V; Wu SR
    Acta Pharmacol Sin; 2023 Jun; 44(6):1161-1174. PubMed ID: 36509902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.